The combination of Ceftriaxone (3rd generation cephalosporin) and Sulbactam (beta-lactamase inhibitor) provides a solution for treatment of such bacterial infections caused betalactam resistant pathogens. Ceftriaxone has a broad spectrum of antibacterial activity is beta-lactamase stable and exhibits excellent activity against Streptococcus pneumoniae, methicillin-susceptible staphylococci, Haemophilus influenzae, Moraxella catarrhalis and Neisseria spp which are the most common cause of community acquired and hospital acquired infections. Ceftriaxone is more potent and hence less protection from a beta- lactamases inhibitor is required for the antibiotic and fewer drug molecules are needed for optimal activity. Fantin et. al. in 1990, showed that the MIC and MBC of ceftriaxone was lowered by addition of sulbactam and the bacterial killing was enhanced proportionately.
| BRAND NAME | MACROCEF – SB 1.5gm |
| COMPOSITION | CEFTRIAXONE 1000GM+SALBACTUM 500MG INJ |
| PACKING | 1.5 MG INJ |
